

EVOTEC AND DEWPOINT THERAPEUTICS ENTER STRATEGIC PARTNERSHIP IN ONCOLOGY

- ▶ STRATEGIC PARTNERSHIP TO ACCELERATE DEWPOINT'S LEADING ONCOLOGY PIPELINE PROGRAMMES TO INVESTIGATIONAL NEW DRUG APPLICATIONS
- ▶ COLLABORATION LEVERAGES EVOTEC'S FULLY INTEGRATED, CLINICAL-ENABLING INDIGO CAPABILITY PLATFORM
- ▶ AGREEMENT IS BASED ON A RISK-SHARING ARRANGEMENT FOLLOWED BY MILESTONE AND ROYALTY PAYMENTS TO EVOTEC BASED ON SUCCESS OF OVERALL PROGRAMMES

Hamburg, Germany, and Boston, USA, 07 November 2023:

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and Dewpoint Therapeutics today announced a strategic R&D collaboration to advance Dewpoint's leading oncology pipeline programmes of condensate modifying therapeutics ("c-mods") to Investigational New Drug Applications ("INDs") using Evotec's industry-leading fully integrated data-driven platform ("INDiGO").

The partnership brings together Dewpoint's advanced oncology pipeline programmes discovered using its groundbreaking condensate biology and A.I. technology platform for identifying modulators of biomolecular condensates with Evotec's leading capabilities to de-risk and accelerate pre-clinical development candidates ("PDCs") to first-in-human ("FIH") clinical studies.

Under the collaboration, Evotec will facilitate the rapid development of Dewpoint's oncology assets using Evotec's fully integrated clinical-enabling INDiGO platform to de-risk and accelerate the path to clinical testing. The partnership also enables Dewpoint to maximise capital efficiency while reducing risk. The agreement is based on a risk-sharing arrangement followed by milestone and royalty payments to Evotec based on the success of the overall programmes.

Dr Matthias Evers, Chief Business Officer of Evotec, commented: "We are excited to enter this strategic development partnership with Dewpoint. Their innovative approach is based on a holistic understanding, which can significantly expand the target space across indications. By combining our complementary expertise, Evotec's development platform will serve as the capital-efficient IND engine

For further information, please contact the Corporate Communications Team:

Hinnerk Rohwedder, Director of Global Corporate Communications, hinnerk.rohwedder@evotec.com;

Gabriele Hansen, SVP Head of Global Corporate Communications, gabriele.hansen@evotec.com, www.evotec.com

for this highly collaborative partnership. We look forward to working closely together with their team to make Dewpoint’s groundbreaking innovations available to patients.”

“Dewpoint’s strategic partnership with Evotec leverages the world-class speed of their development platform to accelerate our oncology assets into the clinic. Evotec’s integrated state-of-the-art operational technologies have been proven to deliver high quality INDs across the industry. A strategic relationship of this nature significantly enhances our development capabilities which can be transformative for a company at our stage of development, and we are delighted to have been able to forge this partnership with a leader like Evotec,” **commented Ameet Nathwani, M.D., CEO at Dewpoint.**

About Condensates

Condensates are membraneless organelles that form dynamically throughout the cell via a process called phase separation. These subcellular compartments organise and concentrate molecules within cells to enable certain key biochemical processes. The dysregulation of biomolecular condensates has been observed in many diseases, including cancer, diabetes and neurological disorders. Condensate-modifying drugs (c-mods) potentially provide novel therapeutic options for complex diseases and historically undruggable targets.

ABOUT DEWPOINT THERAPEUTICS

Dewpoint is the first company to apply the emerging understanding of biomolecular condensates to drug discovery for the vast range of conditions that are regulated by condensates or arise from the dysfunction of condensates. Dewpoint currently has programs across an ambitious pipeline spanning oncology, neurodegenerative, cardiopulmonary and metabolic disease indications, and collaborations with leading global academic and pharmaceutical partners, including Bayer and Novo Nordisk. Dewpoint scientists work in Boston, Dresden and Frankfurt to translate condensate biology into medicine for diseases previously considered untreatable. Learn more at [Dewpointx.com](https://www.dewpointx.com) and follow us on [X](#) and [LinkedIn](#).

Dewpoint Therapeutics Contacts

Media

Media@Dewpointx.com

Investors

Michael Fenn, Ph.D.

Head of External Innovation

MFenn@Dewpointx.com

ABOUT EVOTEC SE

Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company's multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec leverages this "Data-driven R&D Autobahn to Cures" for proprietary projects and within a network of partners including all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 5,000 highly qualified people. The Company's 17 sites offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.com and follow us on X/Twitter [@Evotec](https://twitter.com/Evotec) and [LinkedIn](https://www.linkedin.com/company/evotec).

FORWARD-LOOKING STATEMENTS

This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec's expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.